

Cancer Prone Disease Section

Mini Review

Epidermodysplasia verruciformis

Claude Viguié

Service de Dermatologie, Hôpital Tarnier-Cochin, 89 rue d'Assas, 75006 Paris, France

Published in Atlas Database: June 1998

Online updated version is available from: http://AtlasGeneticsOncology.org/Kprones/epiderm_ver.html DOI: 10.4267/2042/37471

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 1998 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: Levandowsky-Lutz syndrome **Inheritance:** autosomal recessive in 10 to 20 % of the patients; other cases are sporadic; rare disease.

Clinics

Epidermodysplasia verruciformis (EV) is a model of malignant transformation from benign cutaneous viral lesion.



Top left: numerous papule-like warts on the skin of an hand; right: other aspect of papule-like warts on one hand; bottom left: basocellular carcinoma of the face developped from epidermodysplasia verruciformis lesions; right: carcinoma of the face developped from epidermodysplasia verruciformis lesions - Courtesy Daniel Wallach.

Phenotype and clinics

Age at onset is variable; more frequently: young adults or children. Two types of elementary cutaneous lesions are observed:

- Persistant papule-like warts, isolated, or confluent with a psoriasic aspect;
- White spots, pityriasis versicolor-like.

Both types of lesions are localized mainly on the outer part of the hands, on foreharms, legs, face, trunk and perianal zone.

Immunodeficiency: decreased immune response of T lymphocytes to mitogens, decreased humoral response to Human Papilloma Virus antigens; EV lesions have been described in renal transplant recipients.

Various Human Papilloma Virus (HPV) subtypes are regularly detected in the cutaneous lesions: HPV 5, 8, 9, 12, 14, 15, 17, 19, 25, 36, 38, 47, 50.

Patients are simultaneously affected by differents HPV subtypes, according to disease localisation; these subtypes are different from those observed in common warts (HPV 2, 3, 4, 10).

Neoplastic risk

Risk of malignant transformation of cutaneous lesions is within a delay of 20 to 30 yrs (very slow process comparable to the genital carcinogenesis associated with high risk HPVs).

Cytology: squamous cell carcinoma (spinocellular or basocellular carcinoma, Bowen disease).

Correlation with oncogenic subtypes of HPV found in the transformed lesions: HPV 5, 8, 14; the most frequent subtypes are HPV 5 and 8 (90% of cases).

Benign familial forms are associated with HPV 3, without malignant evolution.

HPV-5 is present in the macular lesions.

Probable potentialisation by UV light: 25 to 30% of malignant lesions localised to the face and forehead (hypothetic role of P53 mutations).

Protein E6 and/or E7 (tumour suppressor function) from HPV seem to be involved in the malignant transformation.

Treatment

Surgical resection of localized lesions; chemotherapy with Acitretin (25 mg/j) for multifocal lesions.

Evolution

Local recidives, enhanced by UV exposition.

Genes involved and Proteins

Complementation groups:

Genes and proteins are unknown.

References

Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch of Dermatol 1995;131:1212-8.

Hiraiwa A, Kiyono T, Suzuki S, Ohashi M, Ishibashi M. E7 proteins of four groups of papillomaviruses, irrespective of their tissue tropism or cancer association, possess the ability to transactivate transcriptional promoters E2F site dependently. Virus Genes. 1996;12(1):27-35.

Schaller J, Rohwedder A, Fuchs M, Maron A, Kunze J. HPV-5 typing with nested PCR and sequencing in Epidermodysplasia verruciformis. Hautarzt. 1996 Jun;47(6):454-8.

Stubenrauch F, Leigh IM, Pfister H. E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors. J Virol. 1996 Jan:70(1):119-26.

Bonvalet D, Blanchet-Bardon C, Verola O. Epidermodysplasia verruciformis with numerous squamous cell carcinomas. Nouv Dermatol 1997;suppl1:S1-20.

Hopfl R, Bens G, Wieland U, Petter A, Zelger B, Fritsch P, Pfister H. Human papillomavirus DNA in non-melanoma skin cancers of a renal transplant recipient: detection of a new sequence related to epidermodysplasia verruciformis associated types. J Invest Dermatol. 1997 Jan;108(1):53-6.

Majewski S, Jablonska S. Human papillomavirus-associated tumors of the skin and mucosa. J Am Acad Dermatol. 1997 May;36(5 Pt 1):659-85; quiz 686-8.

Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res. 1997 Oct 1;57(19):4214-6.

McGregor JM, Berkhout RJ, Rozycka M, ter Schegget J, Bouwes Bavinck JN, Brooks L, Crook T. p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomaviruss status. Oncogene. 1997 Oct 2;15(14):1737-40.

Pajunk HS, May C, Pfister H, Fuchs PG. Regulatory interactions of transcription factor YY1 with control sequences of the E6 promoter of human papillomavirus type 8. J Gen Virol. 1997 Dec;78 (Pt 12):3287-95.

Astori G, Lavergne D, Benton C, Hockmayr B. Egawa K, Garbe C, de Villiers EM. Human papillomaviruses are commonly found in normal skin of immunocompetent host. J Invest Dermatol. 1998 May;110(5):752-5.

Bens G, Wieland U, Hofmann A, Hopfl R, Pfister H. Detection of new human papillomavirus sequences in skin lesions of a renal transplant recipient and characterization of one complete genome related to epidermodysplasia verruciformis-associated types. J Gen Virol. 1998 Apr;79 (Pt 4):779-87.

Favre M, Orth G, Majewski S, Balool S, Pura A, Jablonska S. Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol. 1998 Apr;110(4):311-7.

This article should be referenced as such:

Viguié C. Epidermodysplasia verruciformis. Atlas Genet Cytogenet Oncol Haematol.1998;2(4):159-160.